Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period
about
Golimumab for rheumatoid arthritisKv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseasesRate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databasesPredictors of Switching Anti-Tumor Necrosis Factor Therapy in Patients with Ankylosing SpondylitisIndependent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory StudyBiologics registers in RA: methodological aspects, current role and future applications.Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study.Safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries.[Switching within the active ingredient group or changing the mechanism of action. Data situation by failure of the first line biologic].Determinants of biological drug survival in rheumatoid arthritis: evidence from a Hungarian rheumatology center over 8 years of retrospective data.DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonistsPersistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritisWhich subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics RegisterThe impact of patient-perceived restricted access to anti-TNF therapy for rheumatoid arthritis: a qualitative study.Outcomes of switching anti-TNF drugs in rheumatoid arthritis--a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN).Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study).Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study.Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.Impact of comorbidities on TNF inhibitor persistence in rheumatoid arthritis patients: an analysis of Korean National Health Insurance claims data.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsInsights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trialReduction of interleukin-6 expression in human synoviocytes and rheumatoid arthritis rat joints by linear polarized near infrared light (Superlizer) irradiation.Safety and clinical efficacy of golimumab in the treatment of arthritides.The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drugThresholds in disease activity for switching biologics in rheumatoid arthritis patients: experience from a large U.S. cohort.Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study.Primary lack of efficacy of infliximab therapy for rheumatoid arthritis: pharmacokinetic characterization and assessment of switching to tocilizumab.Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitorsImpact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern SwedenPrognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study.Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registryDiscontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors?Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis.Is drug discontinuation risk of adalimumab compared with etanercept affected by concomitant methotrexate dose in patients with rheumatoid arthritis?Do patients with active RA have differences in disease activity and perceptions if anti-TNF naïve versus anti-TNF experienced? Baseline results of the optimization of adalimumab trial.Adalimumab for rheumatoid arthritis.Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort.
P2860
Q24240895-C27BA29C-8504-4ADE-B1F4-C7982EEB04D8Q24676659-F1859E43-ED8E-4E85-8A5A-999E05853CE8Q26778600-91C71F4D-71A6-4410-B15C-89439894D3F9Q28546596-90F08477-A202-428D-87B1-B6A8ED4E8128Q28551216-946674AF-75BF-4730-B31B-347FC2E8A716Q30234303-A39B44CC-7E1E-42B1-BC5D-48ABFF0B9290Q30612910-B31EAEA4-20E2-49DC-8A9A-1E706D95E94CQ30891297-3FB62940-FC8C-4197-A8F5-703B3DEB9CA8Q30962462-899417C7-04BA-4A0B-A3A0-0751FBCFA794Q31167447-C156CD65-AEB3-4E78-B0D3-C29D06D219E0Q33486150-5E45B5DC-85BA-4565-B0A6-373F21A72325Q33563272-910C15F2-401C-45B6-A9B6-20BCB2F5A90CQ33566367-73E959EE-83B8-4989-B715-6BD1FCCCAB5EQ33726924-E6C8DC20-008E-4A70-9E6E-D3BC71A7BE64Q33918359-7BF87F54-7AF7-48C1-889E-57FF13CE6EFCQ33924120-C3E71548-8542-4B6C-A4A6-58BC9526D53FQ34012929-D51DA403-0C46-4434-A64C-52F07281A22FQ34022346-DEDAECA1-C2AD-495B-9A4D-FE08EDF32636Q34027624-C216CCF3-D20A-4E45-AEF5-D9C8B82AA550Q34109394-3394203A-DF55-4C09-97D9-35671100CD8FQ34110066-9DDD9FDE-BE1B-40B9-9FE1-90DA46E440C1Q34237578-0206E54F-DE30-4CE8-A674-18FCEF1DD439Q34795777-4C52BC0D-5C47-4D48-A297-8390AC4478E3Q35025084-7A67536A-3AF3-49AE-A94A-E5B23008BF19Q35026454-71FF8DF9-0E9E-42B7-89E7-822139BB8D8DQ35336802-500F4A0A-9F19-4E7F-861C-C21CC84DE983Q35583230-AD1166C2-7EE6-409E-ADA0-5EE89A80DEA2Q35605438-F8F7A8FF-34DE-471E-B27A-C7AA428DF148Q35610243-54AE9068-EF6B-477D-8C4A-A8ED142ABE88Q35620336-4297EAD4-2F29-4118-9A39-4C282F87E6FBQ35630063-81EBFE07-220E-41D4-9170-A1B0459C97F5Q35728708-2810730F-C76B-4027-AB20-1E9917769857Q35954640-BCC3DD66-A3A9-492B-9E8A-2389678CCCDDQ36267465-BC875ED5-1C9D-4FAA-A89D-10D899769EF0Q36302246-3DA199D2-8498-45AF-9E6D-093B6F0B0F57Q36331865-4C940BE0-3DE3-4E87-A041-8F5665FEF1FDQ36575283-FF8097C4-6BA1-4786-B94C-5BC51750F297Q36577308-9B94BA60-2BCF-4B07-B673-B4BF81644D3FQ36708319-5A1A5623-3431-41C6-88BB-25E00E5363D2Q36715135-7D87C267-C605-4E21-99DE-54C91549E069
P2860
Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Switching TNF antagonists in p ...... tients over a four-year period
@ast
Switching TNF antagonists in p ...... tients over a four-year period
@en
Switching TNF antagonists in p ...... tients over a four-year period
@nl
type
label
Switching TNF antagonists in p ...... tients over a four-year period
@ast
Switching TNF antagonists in p ...... tients over a four-year period
@en
Switching TNF antagonists in p ...... tients over a four-year period
@nl
prefLabel
Switching TNF antagonists in p ...... tients over a four-year period
@ast
Switching TNF antagonists in p ...... tients over a four-year period
@en
Switching TNF antagonists in p ...... tients over a four-year period
@nl
P2860
P356
P1476
Switching TNF antagonists in p ...... tients over a four-year period
@en
P2093
BIOBADASER Group
Juan J Gomez-Reino
P2860
P2888
P356
10.1186/AR1881
P577
2006-01-06T00:00:00Z
P5875
P6179
1013480577